Stockreport

Oruka Therapeutics Announces Positive Interim Phase 1 Data for ORKA-002 and Initiation of EVERLAST-B Trial of ORKA-001 [Yahoo! Finance]

Oruka Therapeutics, Inc.  (ORKA) 
PDF Phase 2 studies for ORKA-002 expected to begin in 1H 2026 for psoriasis and 2H 2026 for hidradenitis suppurativa First patients dosed in EVERLAST-B Phase 2b trial of [Read more]